Bristol-Myers Squibb Co (BMY) Financials

Bristol-Myers Squibb Co (BMY) is a global biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to patients with serious diseases. The company's income statement reflects its financial performance over a specific period, highlighting its revenues, expenses, and resulting net income. It provides valuable insights into the company's profitability and growth. For Bristol-Myers Squibb Co, the income statement portrays its revenue, gross profit, EBIT (earnings before interest and taxes), and net income. These metrics showcase the company's financial health and ability to generate profits. Additionally, EBITDA (earnings before interest, taxes, depreciation, and amortization) represents a measure of earnings that excludes non-operating expenses and provides a clearer picture of the company's operating performance.

Bristol-Myers Squibb Co's balance sheet illustrates the company's financial position at a specific date. It consists of its assets, liabilities, and stockholders' equity. Total assets represent the company's resources, including cash equivalents, while total liabilities reflect its obligations. Stockholders' equity represents the residual interest of the company's owners after deducting liabilities. Additionally, total debt represents the company's borrowing obligations. It is essential to analyze the balance sheet to understand the company's financial stability and ability to meet its obligations. Moreover, cash flow is crucial as it provides insights into how BMY manages its cash and cash equivalents. Operating cash flow refers to the cash generated from the company's core operations, while investing cash flow represents cash used for investments. Financing cash flow reflects cash flows related to fundraising activities, such as issuing stocks or repurchasing shares. Free cash flow, calculated as operating cash flow minus capital expenditures, measures the company's ability to generate cash after accounting for its capital needs. Overall, analyzing Bristol-Myers Squibb Co's financials is vital to assess its financial performance, stability, and growth prospects.